The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Aldara, Zyclara Pump, Zyclara
Synonyms :
Class :
Antineoplastic topical
Brand Name :
Aldara, Zyclara Pump, Zyclara
Synonyms :
Class :
Antineoplastic topical
Dosage Forms & Strengths
Topical cream
2.5%
3.75%
5%
Apply 5% cream topically to affected area 5 times per week 6 weeks
Apply 3.75% cream to external genital warts once a day 8 weeks
Apply 2.5%/3.75% cream to the affected area once a day
Dosage Forms & Strengths
Topical cream
2.5%
3.75%
5%
Age: > 12 years Apply 3.75% cream to the external genital warts 8 weeks
may increase the serum concentration of each other when combined
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
acetaminophen and phenyltoloxamine
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may decrease the therapeutic effect when combined with lenograstim
may diminish the therapeutic effect when combined with lipegfilgrastim
may increase the adverse effect when combined with antineoplastic agents
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
abiraterone acetate and niraparib
may decrease the therapeutic effect of Immunosuppressants
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may decrease the therapeutic effect of immunosuppressive Agents
measles, mumps, rubella, and varicella vaccine, live
may decrease the therapeutic effect of immunosuppressive Agents
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of immunosuppressive Agents
may decrease the therapeutic effect of immunosuppressive Agents
smallpox (vaccinia) vaccine, live
may decrease the therapeutic effect of immunosuppressive Agents
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
it enhance the risk of pulmonary toxicity
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
Adverse drug reactions:
Frequency Not Defined
Birth defects
Burning
Pain
Pruritus
Headache
Insomnia
Irritability
Rash
Photosensitivity
Leukocytosis
Herpes simplex
Allergic contact dermatitis
Thrombocytopenia
Inflammation
Miscarriage
Pregnancy warnings:
AU TGA pregnancy category: B1
US FDA pregnancy category: C
Lactation:
Excreted into human milk is Unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: imiquimod topical
Why do we use imiquimod topical?
imiquimod topical is an Antineoplastic topical agent which is used to treat Actinic Keratosis and Basal Cell Carcinoma.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
